MORE than half of patients diagnosed with non-Hodgkin lymphoma (NHL) are now surviving the cancer thanks to improved diagnosis and treatment, campaigners have saidContinue reading
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drugContinue reading
Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma ...
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapyContinue reading
The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for ...
WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6 million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and CaliberContinue reading
In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certainContinue reading
Provincial drug plans adding new lymphoma treatment is good news for patients, but other promising cancer therapies ...
Faster approvals needed for coverage by provincial drug plans: Lymphoma Foundation Canada TORONTO, April 24, 2013 /CNW/ - The recent approval by Health Canada of a highly effective new treatment for non-HodgkinContinue reading
( John Theurer Cancer Center ) John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pmContinue reading
Non-Hodgkin lymphoma is the seventh most common form of cancer in the United States, and doctors may have found a new way to treat it. Some forms of the lymphoma respond well to treatment, but others are stubborn and aggressive. Now, a new discovery may change the way doctors treat the most difficult cases. Researchers are using the concept that in order to kill the enemy, you must target theContinue reading
“What doesn’t kill you makes you strongerContinue reading
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at theContinue reading